1-2 of 2
Lindy K. Alles
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

RAS–MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma

Thomas F. Eleveld, Linda Schild, Jan Koster, Danny A. Zwijnenburg, Lindy K. Alles, Marli E. Ebus, Richard Volckmann, Godelieve A. Tijtgat, Peter van Sluis, Rogier Versteeg, Jan J. Molenaar
Journal: Cancer Research
Cancer Res (2018) 78 (21): 6297–6307.
https://doi.org/10.1158/0008-5472.CAN-18-1045
Published: 01 November 2018
View article titled, RAS–MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma
Open the PDF for RAS–MAPK Pathway-Driven Tumor Progression Is Associated with Loss of CIC and Other Genomic Aberrations in Neuroblastoma in another window
Includes: Supplementary data
Journal Articles

Abstract 2630: Preclinical identification of Venetoclax combination strategies with Idasanutlin, CUDC-907, Prexasertib or Talazoparib for neuroblastoma treatment

M. Emmy M. Dolman, Laurel T. Bate-Eya, Lindy Vernooij, Bianca Koopmans, Lindy K. Alles, Anke H. Essing, Daphne Lelieveld, David A. Egan, Mark Kerstjens, Ronald W. Stam, Huib N. Caron, Jan J. Molenaar
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): 2630.
https://doi.org/10.1158/1538-7445.AM2018-2630
Published: 01 July 2018
View article titled, Abstract 2630: Preclinical identification of Venetoclax combination strategies with Idasanutlin, CUDC-907, Prexasertib or Talazoparib for neuroblastoma treatment